Truist lowered the firm’s price target on Ardent Health (ARDT) to $13 from $21 and keeps a Buy rating on the shares. The company reported Q3 results where solid core volume and demand trends were overshadowed by an acceleration in Professional fees and payor denials, which weighed on the quarter and drove lowered FY25 guidance, the analyst tells investors in a research note. Truist adds however that solid financial flexibility should support ongoing capacity expansion and underpin growth investment and M&A for Ardent.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $12 from $19 at Goldman Sachs
- Ardent Health price target lowered to $17 from $21 at Stephens
- Cautious Hold on Ardent Health Partners Amidst Guidance Cuts and Competitive Disadvantages
- Ardent Health downgraded to Equal Weight from Overweight at Morgan Stanley
- Ardent Health Reports Q3 2025 Financial Results